Business
Universal Ibogaine Commences Trading on the TSX-V
(TheNewswire) Calgary, AB – TheNewswire - October 5, 2021 ...
About this update from Universal Ibogaine Inc
[{"type":"text","content":"Universal Ibogaine Commences Trading on the TSX-V\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n Calgary, AB –\n \n \n TheNewswire -\n \n \n October 5, 2021 – Universal Ibogaine Inc.\n(TSXV:IBO) (“Universal Ibogaine”, “UI” or the “Company”),\n \n \n a life sciences company with a mission to\ndeliver medicalized ibogaine-centered addiction care, is pleased to\nannounce the commencement of trading today of its common shares on the\nTSX Venture Exchange (“TSXV”) under the symbol “IBO”.\n \n \n \n \n The Company’s news release of October 1, 2021,\nadvised of the approval of listing of UI’s common shares by way of\nissuance of the Final Exchange Bulletin by the TSXV, and included\ndetails of the number of common shares which will be subject to future\nescrow and legend restrictions.\n \n \n \n \n \n Universal Ibogaine aims to help solve\nthe opioids crisis, generating a sustainable change in the lives of\npeople living with addiction, and positively transforming the way\naddiction is viewed.\n \n \n \n \n \n \n UI intends to develop innovative\naddiction treatments starting with clinical trials research into\nibogaine, as well as treat addiction in clinics by creating and\nrolling out a state-of-the-art holistic addiction treatment model.\n \n \n \n Ibogaine has been shown to decrease\nwithdrawal symptoms and associated cravings to opioids such as\noxycodone, heroin, and fentanyl, and has shown effectiveness in\ndisrupting addiction to other substances such as alcohol and\ncocaine.  The UI addiction treatment model intends to extend from\nmedical detoxification to rehabilitation & aftercare, as well as\nincreasing effectiveness and minimizing relapse.\n \n \n \n \n From Dr. Rami Batal, UI’s Chief\nExecutive Officer:\n \n \n \n \n “We thank our shareholders for their unwavering\nsupport and patience throughout the listing process. We are excited to\nnow focus on our growth plan related to rolling out our addiction\ntreatment offering starting with the Kelburn Clinic, as well as\nresearch into clinically developing and ultimately medicalizing\nibogaine to become a central treatment for opioid and other\naddictions. The plan forward calls on engagement and close\ncoordination with Health Canada through a cli...